Table 4.
Gene set enrichment analysis (GSEA) for enrichment of gene sets/pathways for the up-regulated and down-regulated genes in participants with MI compared to controls
| NAME in the Molecular Signatures Database (MSigDB) | SIZE | NES | NOM p-val |
FDR q-val |
|---|---|---|---|---|
| BOWIE_RESPONSE_TO_EXTRACELLULAR_MATRIX | 17 | 0.834137 | 0 | 0 |
| DAZARD_UV_RESPONSE_CLUSTER_G4 | 15 | 0.810541 | 0 | 0 |
| BOWIE_RESPONSE_TO_TAMOXIFEN | 18 | 0.800464 | 0 | 0 |
| ZHANG_INTERFERON_RESPONSE | 22 | 0.760159 | 0 | 5.99E-04 |
| BENNETT_SYSTEMIC_LUPUS_ERYTHEMATOSUS | 30 | 0.730185 | 0 | 0.001917 |
| ZHANG_ANTIVIRAL_RESPONSE_TO_RIBAVIRIN_UP | 20 | 0.724651 | 0 | 0.002397 |
| CREIGHTON_AKT1_SIGNALING_VIA_MTOR_DN | 20 | 0.687019 | 0 | 0.009875 |
| UROSEVIC_RESPONSE_TO_IMIQUIMOD | 20 | 0.687635 | 0 | 0.011115 |
| STAMBOLSKY_TARGETS_OF_MUTATED_TP53_DN | 38 | 0.67526 | 0 | 0.012077 |
| CHIBA_RESPONSE_TO_TSA_UP | 29 | 0.677011 | 0 | 0.012327 |
| DAZARD_UV_RESPONSE_CLUSTER_G24 | 15 | 0.680731 | 0.001965 | 0.012367 |
| MOSERLE_IFNA_RESPONSE | 29 | 0.670738 | 0 | 0.013561 |
| EINAV_INTERFERON_SIGNATURE_IN_CANCER | 26 | 0.662667 | 0 | 0.016484 |
| GALE_APL_WITH_FLT3_MUTATED_DN | 16 | 0.652891 | 0 | 0.019301 |
| LIANG_SILENCED_BY_METHYLATION_2 | 32 | 0.654796 | 0 | 0.02017 |
| LIANG_HEMATOPOIESIS_STEM_CELL_NUMBER_QTL | 15 | 0.653422 | 0.006276 | 0.020191 |
| JOSEPH_RESPONSE_TO_SODIUM_BUTYRATE_UP | 26 | 0.645603 | 0 | 0.021225 |
| REACTOME_TRANSFERRIN_ENDOCYTOSIS_AND_RECYCLING | 19 | 0.646882 | 0 | 0.021409 |
| RASHI_NFKB1_TARGETS | 18 | 0.648308 | 0 | 0.021688 |
| CAVARD_LIVER_CANCER_MALIGNANT_VS_BENIGN | 16 | 0.639799 | 0.001927 | 0.024119 |
| DAUER_STAT3_TARGETS_DN | 46 | 0.63281 | 0 | 0.026719 |
| HARRIS_BRAIN_CANCER_PROGENITORS | 15 | 0.633145 | 0.00404 | 0.027771 |
| KRASNOSELSKAYA_ILF3_TARGETS_UP | 28 | 0.633243 | 0 | 0.029035 |
| RADAEVA_RESPONSE_TO_IFNA1_UP | 47 | 0.626684 | 0 | 0.030557 |
| KIM_LRRC3B_TARGETS | 28 | 0.626813 | 0 | 0.03178 |
| SUH_COEXPRESSED_WITH_ID1_AND_ID2_UP | 16 | 0.623882 | 0.005906 | 0.032143 |
| NOJIMA_SFRP2_TARGETS_DN | 18 | 0.621049 | 0.002024 | 0.034003 |
| XU_HGF_TARGETS_INDUCED_BY_AKT1_6HR | 16 | 0.60961 | 0.008065 | 0.039922 |
| BROWNE_INTERFERON_RESPONSIVE_GENES | 63 | 0.610055 | 0 | 0.040405 |
| REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 46 | 0.610758 | 0 | 0.040506 |
| GRATIAS_RETINOBLASTOMA_16Q24 | 15 | 0.611119 | 0.00813 | 0.041194 |
| KANG_CISPLATIN_RESISTANCE_UP | 16 | 0.611884 | 0 | 0.041448 |
| WELCH_GATA1_TARGETS | 18 | 0.613601 | 0 | 0.042096 |
| OUYANG_PROSTATE_CANCER_PROGRESSION_DN | 16 | 0.612352 | 0.004008 | 0.042214 |
| REACTOME_INSULIN_RECEPTOR_RECYCLING | 17 | 0.601722 | 0 | 0.049199 |
A total of 3283 gene sets in GSEA C2 category [28] were tested. At FDR < 25% enrichment level, 215 gene sets were significantly up-regulated (out of 1938) and eight gene sets were significantly down-regulated (out of 1345)
NES Normalized enrichment score, NOM p-val Nominal p-value, FDR q-val False discovery rate q-value